Because economic evaluations of health care services are being published with increasing
frequency it is important to (a) evaluate them rigorously and (b) compare the net benefit of …

W e thank Gafni and Birch (see pages 913 to 917) and Naylor and associates (see pages
921 to 924) for their thoughtful and useful comments on our paper in which we outlined tenta …

The guidelines proposed by Laupacis and associates do not stem from economic theory and
are a prescription for uncontrolled growth in health care expenditure. In particular, cost …

The health care system is routinely confronted with promising new technologies. In the past,
most new technologies have been integrated into clinical practice without a rigorous …

We believe that the systematic evaluation of medical practices, especially those that are
risky or costly, deserves more attention. Available methods are limited, and definitive …

Since the advent of Medicare's prospective payment system, beneficial but cost-increasing
medical advances have been systematically assigned to existing diagnosis-related groups …

In medical technology assessment, randomized control trials (RCTs) play an important role
in determining the relative efficacy of compared treatments. As scarce resources necessitate …

This report includes 16 papers which were presented at a 1977 symposium convened by the
Sun Valley Forum on National Health to examine the relationship between medical …

Health economists should be wary of estimates of clinical effectiveness. Clinicians and the
pharmaceuticals industry are always exaggerating the benefit of new drugs. They become …

Investigators often compare new and old technologies, and in such comparisons physicians
may wish to know how often patients would respond better with the new technology. In other …